The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
ApexOnco Front Page
Recent articles
BeOne's degrader BG-60366 appears to have been discontinued.
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.
Supply continues to cause headaches for radiopharmaceutical developers.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
The group is keeping faith with the novel target KLK2.
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.